Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 2Active not recruiting 2Recruiting 1Enrolling by invitation 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 4Sarcoma 2Gynecologic 2CNS 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Mucopolysaccharidosis I 1Breast Neoplasms 1

Interventions

Trastuzumab 379Paclitaxel 369Cyclophosphamide 338Docetaxel 314Capecitabine 198Doxorubicin 196Letrozole 183Tamoxifen 154Carboplatin 153Fulvestrant 136Bevacizumab 129Anastrozole 120exemestane 119Lapatinib 117Epirubicin 116Gemcitabine 112Radiotherapy 107palbociclib 93Exercise 87Fluorouracil 83Vinorelbine 82Surveys and Questionnaires 81pertuzumab 77Albumin-Bound Paclitaxel 76Filgrastim 71130-nm albumin-bound paclitaxel 64pembrolizumab 63Everolimus 59Cisplatin 59eribulin 58

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Combined Modality Therapy × Breast × Clear all
NCT03411161 2021-05-25

S 81694 Plus Paclitaxel in Metastatic Breast Cancer

Servier

Phase 1/2 Completed
22 enrolled
Breast

Breast Neoplasms, Mucopolysaccharidosis I, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡